60
Participants
Start Date
November 30, 2011
Primary Completion Date
December 31, 2012
Study Completion Date
June 30, 2015
Nab paclitaxel
Nab-paclitaxel 125 mg/m2 will be administered IV over 30 minutes. Nab-paclitaxel will be administered weekly for 3 weeks followed by 1 week of rest (28-day cycle).
Gemcitabine
Following the completion of nab-paclitaxel administration, gemcitabine IV infusion at 1000 mg/m2 will be administered over 30 minutes. Gemcitabine will be administered weekly for 3 weeks followed by 1 week of rest (28-cycle).
Dociparstat
Following the completion of gemcitabine administration, dociparstat IV bolus at 4 mg/kg will be administered in 5 minutes immediately after completion of gemcitabine administration. Immediately following the dociparstat IV bolus administration, dociparstat 48-hour IV continuous infusion at 0.375 mg/kg/hr will be administered.
UPMC Cancer Center, Pittsburgh
Thomas Jefferson University [Kimmel Cancer Center], Philadelphia
Fox Chase Cancer Center, Philadelphia
Medical University of South Carolina Hollings Cancer Center, Charleston
Cleveland Clinic Florida, Weston
Summa Health System - Cooper Cancer Center, Akron
Indiana University Health, Goshen Center for Cancer Care, Goshen
Saint Mary's Health Care, Grand Rapids
Loyola University Medical Center/Cardinal Bernardin Cancer Center, Maywood
Fesit-Weiller Cancer Center, Shreveport
University of Texas Medical Branch, Galveston
South Texas Oncology & Hematology, San Antonio
Mayo Clinic Arizona, Scottsdale
Disney Family Cancer Center, Burbank
Scripps Clinic Torrey Pines ( Green Hospital), La Jolla
Marin Cancer Care, Greenbrae
Lead Sponsor
Translational Drug Development
OTHER
Jazz Pharmaceuticals
INDUSTRY